Plasma cell dyscrasias

Plasma cell dyscrasias are a heterogeneous group of disorders caused by the monoclonal proliferation of plasma cells in the bone marrow. Multiple myeloma is the most prevalent plasma cell dyscrasia and the second most frequent hematologic malignancy. Other plasma cell dyscrasias include monoclonal gammopathy of undetermined significance, solitary plasmacytoma, AL amyloidosis, POEMS syndrome, and heavy-chain diseases.

Filter by content:

  • Types
    AL amyloidosis
    BRAF
    Chromosomal aberrations
    COVID-19
    Deletion 13q
    Deletion 17p
    Deletion 1p
    Favorable-risk
    Gain 1q
    High-risk
    KRAS
    MGC
    MGRS
    MM-related mutations
    MYC
    Newly diagnosed multiple myeloma
    NRAS
    PCL-like MM
    Plasma cell dyscrasias
    Plasma cell leukemia
    Relapsed/refractory multiple myeloma
    Risk
    Smoldering multiple myeloma
    Solitary plasmacytoma
    TP53
    Translocation (11;14)
    Translocation (14;16)
    Translocation (14;20)
    Translocation (4;14)
    Transplant-ineligible MM
    Trisomy 21

Therapeutics
Acalabrutinib
ALLO-501
ALLO-605
ALLO-647
ALLO-715
Allo-HSCT
Allo-NKT
Alnuctamab
AMG 420
AMG 701
Anakinra
Anitocabtagene autoleucel
Anselamimab
Antibody recruiting molecules
Antibody therapy
AO-176
ARI0002h
Arlocabtagene autoleucel
Atezolizumab
Auto-HSCT
Auto-NKT
Avelumab
bb21217
BCL-2 inhibitors
BCMA CAR-T
Belantamab mafodotin
Bendamustine
BHV-1100
Binimetinib
Birtamimab
Blinatumomab
Bortezomib
Busulfan
CAEL-101
CAR NK cells
CAR therapy
Carfilzomib
CART-dd
BCMACB-011
CC-92480
CC-93269
CC-95266
CD138 CAR-T
CD19 CAR-T
Cellular therapy
Cemsidomide
Cevostamab
CFT7455
Checkpoint inhibitors
Chemotherapy
Ciltacabtagene autoleucel
Clodronate
Conjugated antibodies
CS1 (SLAMF7) CAR-T
Cyclophosphamide
Daratumumab
Dasatinib
Denosumab
Descartes-11
Dexamethasone
Doxorubicin
Durvalumab
Elotuzumab
Elranatamab
EM801
Encorafenib
Equecabtagene Autoleucel
Etentamig
Etoposide
Fludarabine
Forimtamig
GC012F
Gemcitabine
HBI0101
HDAC inhibitors
HDP-101
HPN217
Iberdomide
IBI3003
Ibrutinib
Idecabtagene vicleucel
Immune modulators
Inobrodib
Iopofosine I 131
Isatuximab
ISB 1342
ISB 1442
ISB 2001
Ixazomib
KLN-1010
KMCARLBL-034
Lenalidomide
Linvoseltamab
MCARH109
MEDI2228
Melflufen
Melphalan
Mezigdomide
Modakafusp alfa

Congresses
2021 Symposium
2022 Symposium
2023 Hub event
2024 Symposium
AACR 2020
AACR 2023
American Society of Hematology
ASCO 2017
ASCO 2018
ASCO 2019
ASCO 2020
ASCO 2021
ASCO 2022
ASCO 2023
ASCO 2024
ASCO 2025
ASCO 2026
ASH 2017
ASH 2018
ASH 2019
ASH 2020
ASH 2021
ASH 2022
ASH 2023
ASH 2024
ASH 2025
CAR-T 2020
CAR-T 2021
CAR-T 2022
CAR-T 2023
CAR-T 2024
CAR-T 2025
COMy 2018
COMy 2019
COMy 2020
COMy 2021
COMy 2022
COMy 2023
Controversies in Multiple Myeloma
EBMT 2019
EBMT 2020
EBMT 2021
EBMT 2022
EBMT 2023
EBMT 2024
EHA 2017
EHA 2018
EHA 2019
EHA 2020
EHA 2021
EHA 2022
EHA 2023
EHA 2024
EHA 2025
EHA 2026
EMN 2021
EMN 2022
EMN 2024
ESH 2017
ESH 2018
ESH 2019
ESH 2020
ESH 2021
ESH 2024
ESMO 2022
European Hematology Association
European Society for Blood and Marrow Transplantation
IACH 2024
IMS 2022
IMS 2023
IMS 2024
IMS 2025
IMS Workshop 2023
IMS Workshop 2024
IMW 2019
IMW 2021